Fostrox plus Lenvatinib for advanced liver cancer after immunotherapy
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding the drug Fostrox to the standard drug Lenvatinib works better than Lenvatinib alone for people with advanced liver cancer that has worsened after initial immunotherapy treatment. It is for those who cannot have surgery and have not had more than one prior cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer that cannot be removed by surgery and has spread.
- You have already received at least 2 rounds of an immunotherapy combination (like atezolizumab + bevacizumab) and your cancer got worse.
- You have at least one measurable tumor in the liver that has not been treated locally or has grown after local treatment.
- You are in generally good health (able to do daily activities) and have adequate liver and blood function.
- You have not had more than one previous cancer treatment for advanced disease and no prior TKI drugs like lenvatinib.
- You have no uncontrolled heart problems, bleeding risks, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two oral targeted therapy drugs, lenvatinib and regorafenib, in people with advanced liver cancer (hepatocellular carcinoma) that has progressed after first-line immunotherapy-based treatment. The goal is to see if these drugs can control the cancer and improve outcomes.
This trial tests a combination of two or three drugs for advanced liver cancer that cannot be removed with surgery. The goal is to see if adding a third drug (gefitinib) to the standard two-drug combination helps patients live longer with better quality of life.
This trial tests a new combination of chemotherapy (FOLFOX) plus atezolizumab and bevacizumab for people with advanced liver cancer that has grown after having atezolizumab and bevacizumab alone. The goal is to see if adding chemo helps stop the cancer from growing further.
This trial tests whether combining two targeted drugs (lenvatinib and tislelizumab) works better than lenvatinib alone for people with advanced liver cancer whose disease worsened after prior treatment with an immunotherapy and a blood vessel growth blocker (bevacizumab).
This trial tests a combination treatment for advanced liver cancer that cannot be removed with surgery. It combines a procedure (irreversible electroporation) that uses electrical pulses to destroy cancer cells, with targeted therapy (lenvatinib) and immunotherapy (sintilimab) to help your immune system fight the cancer.
This trial tests a combination of three treatments—chemo given directly into the liver, an oral targeted therapy, and an immunotherapy—for people with liver cancer that could be removed by surgery but isn't the first choice right now. The goal is to see if this combination can shrink the tumor and improve outcomes before surgery.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.